0:00
I'm Derek O'Hagan.
I work for GSK Vaccines.
I research in Cambridge.
I'm going to be talking
about vaccine adjuvants.
Although I'm an employee
of GSK Vaccines,
the presentation I'm
going to make really
reflects my experience
across a number of companies,
and it doesn't really
express the policy of GSK.
0:23
So in trying to define vaccine
adjuvants and what they are,
it's not an easy task to accomplish.
Essentially, they are
defined by what they do.
They enhance the immune
response to a vaccine antigen.
So since there's no
clear definition,
there are many, many diverse
substances in the literature that
have been described
as vaccine adjuvants,
particularly in a
pre-clinical setting.
If we try to understand a little
better those that have progressed
to clinical trials, we can
get a better appreciation
of some of the materials,
because a smaller
percentage of advanced trials.
And even a very small
percentage of these
have eventually been included
in licensed vaccines.
And these are the
adjuvants I'm mostly going
to focus on for obvious reasons.
It's a very diverse area.
There many materials, but
I'm going to focus on those
that have been most advanced.
